The hemostasis and coagulation analyzer market primarily includes point-of-care hemostasis testing analyzers and clinical laboratory hemostasis testing analyzers that are used to test various blood coagulation parameters and processes for diagnostic and treatment monitoring purposes. These analyzers measure parameters like coagulation factors, fibrinogen levels, D-dimer and prothrombin time and help detect bleeding disorders, determine therapy, and monitor anticoagulant drug therapy among others. The advantages of these analyzers are that they provide fast and automated testing methods for hemostasis and coagulation parameters as compared to traditional manual methods. Considering the rising lifestyle and chronic diseases like cardiovascular diseases and cancer which require coagulation monitoring, there is a growing need for these analyzers in hospitals, clinics and diagnostic centers.
The Global Hemostasis/ Coagulation Analyzer Market is estimated to be valued at US$ 6.47 Bn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Hemostasis/ Coagulation Analyzer Market Growth are Horiba Medical, Siemens Healthineers AG, Agappe Diagnostics Ltd, NIHON KOHDEN CORPORATION, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Stago Group, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific Inc., Haemonetics Corporation, Genrui Biotech Co., Ltd., BIOLABO S.A.S, Erba Mannheim, Sclavo Diagnostics International, and Helena Laboratories Corporation. Second paragraph is talking about the growing demand in market and third paragraph is talking about global expansion of market.
The global hemostasis and coagulation analyzer market is expected to witness significant growth over the forecast period driven by the steadily increasing global incidence of chronic diseases such as cardiovascular diseases, cancer, diabetes as well as rising demand for point-of-care testing. Coagulation disorders occur frequently in cancer, and monitoring of coagulation parameters is vital during cancer diagnosis and treatment which will boost the demand for these analyzers. Furthermore, technological advancements leading to the development of advanced rapid point-of-care testing analyzers will augment the adoption across healthcare settings.
Geographically, North America is anticipated to dominate the global market over the forecast years owing to increasing healthcare expenditure, availability of advanced hemostasis testing products, and presence of leading market players in the region. However, the Asia Pacific region is projected to exhibit the highest growth rate owing to improving access to diagnostics, increasing healthcare spending, rising patient pool of chronic diseases in counties like China and India. Product launches and expansions into emerging markets will further aid in the global expansion of key hemostasis and coagulation analyzer companies.